Sanphar's Asian subsidiary claims successful PEDV vaccine trials
Singapore-based company Sanphar Asia has completed successful trials for a potential vaccine to combat the deadly porcine epidemic diarrhea virus (PEDV) in pigs.
The clinical trials were conducted in Thailand and the company claimed positive clinical and virological results were obtained for oral and injected formulations of the vaccine.
Sanphar said it undertook the trials using Singaporean company ACM Biolabs' proprietary artificial cell membrane (ACM) technology. The study investigated the efficacy of using ACM technology to provide immunity against PEDV virus in pigs.